Alemtuzumab

A4DAB009 | Cancer | Approved

Target CD52

Isotype / Subclass G1 / IgG1

Company

Bayer HealthCare Pharmaceuticals Inc. Dana-Farber Cancer Institute German CLL Study Group Ohio State University Comprehensive Cancer Center Sanofi Sanofi Oncology University of Cologne University of Cambridge

Clinical Status Approved

Format Whole mAb

Synonyms

Campath Campath-1H LDP-03 LDP03 Lemtrada Remniq

pH Formulation 6.8-7.4

IMGT PubChem (7978474) PubChem (46507379) PubChem (50070197) PubChem (103771414) PubChem (135330159) PubChem (178103376) PubChem (329976974) PubChem (384494226) PubChem (440790671) PubChem (464013610) PubChem (468568987) PubChem (472398050) PubChem (481101485) PubChem (481155365) PubChem (496156079) PubChem (498146340) PubChem (505184773) PubChem (519839756) Thera-SAbDab YAbS

Avg A4D Score

-0.7715

Score Range

-0.79 to -0.76

Structures

Structure ID	Source PDB	Seq. Identity	Avg. A4D Score	pH (Min Agg.)	pH (Max Agg.)	Score CDR	Score non-CDR
A4DAB009_1ce1_H_L	1ce1	100%	-0.7572	6.5	9.0	-0.9384	-0.7345
A4DAB009_1bey_H_L	1bey	100%	-0.7858	6.5	9.0	-0.8999	-0.7712

Alemtuzumab

Avg. A4D Score per Structure

pH at Min / Max Aggregation Propensity

Associated Structural Profiles Level 2